TIRZEPATIDE/GLYCINE 16.6MG/7.5MG/ML 4.5Ml

Tirzepatide / Glycine 16.6 mg / 7.5 mg per mL – 4.5 mL Vial is a compounded injectable formulation designed for research and clinical interest in metabolic regulation, glycemic control, and weight management. Tirzepatide 16.6 mg/mL – Tirzepatide is a dual GLP-1 and GIP receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and promotes satiety. These mechanisms contribute to significant reductions in blood glucose levels and body weight. A 4.5 mL vial contains a total of approximately 74.7 mg of tirzepatide. It is FDA-approved under Mounjaro for type 2 diabetes. Glycine 7.5 mg/mL – Glycine is a non-essential amino acid involved in protein synthesis, neurotransmission, and metabolic regulation. It may support insulin sensitivity, antioxidant activity, and overall metabolic balance. The vial contains a total of 33.75 mg of glycine. This sterile solution is intended for subcutaneous injection in controlled clinical or investigational settings. The combination leverages tirzepatide’s potent incretin-based metabolic effects with glycine’s supportive role in metabolic and cellular function. Clinical outcomes and metabolic effects of tirzepatide: https://pubmed.ncbi.nlm.nih.gov/33657290/ Mechanism of GLP-1/GIP receptor agonists: https://pubmed.ncbi.nlm.nih.gov/34534432/